Total Funding
50
55
Total FundingPost-IPO Equity raised
Growth Score
-19 pts
Heat Score
-7 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
67449
Black Diamond Therapeutics is a medical company focused on analyzing genetically defined cancers.
- David M. Epstein: Founder, President & Chief Executive Officer
- Tai-An Lin: Senior Vice President, Translatonal Science and Discovery Biology
About the Company
Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery and development of small-molecule. It is engaged in discovering and developing small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, Mutation-Allostery-Pharmacology, which targets cancer mutations.
Black Diamond
focuses on the discovery and development of precision medicines for cancer that are directed against a novel class of allosteric mutant oncogenes. It also targets undrugged mutations in patients with genetically defined cancers for whom limited treatment options currently exist. It is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry.
Women Founded
